Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-121 · 1 trial · 1 indication
UPCR is urine protein-to-creatinine ratio
| Arm | Type | Description |
|---|---|---|
| ARGX-121 | EXPERIMENTAL | Participants will receive ARGX-121 in subcutaneous injections during the double blinded treatment period and active only treatment periods (Total of 52 weeks) |
| Placebo followed by ARGX-121 | PLACEBO_COMPARATOR | Participants receive placebo for the double-blinded period of 24 weeks, followed by subcutaneous injections of ARGX-121 during the active only treatment period of 28 weeks. |
| Name | Type | Description |
|---|---|---|
| ARGX-121 | BIOLOGICAL | Subcutaneous Injection of ARGX-121 |
| Placebo | BIOLOGICAL | Subcutaneous Injection of Placebo |
Inclusion Criteria: * Males and females (not pregnant) * At least 18 years old * Clinically diagnosed with IgAN with biopsy confirmation Exclusion Criteria: * Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of Ig...
ARGX-121 is an investigational monoclonal antibody being developed for Immunoglobulin A Nephropathy (IgAN), a kidney disease. It is in Phase 2 clinical development and is designed to reduce proteinuria in adults with the condition. It is not approved for any use.
ARGX-121 targets immunoglobulin A (IgA), a protein. By binding IgA, the monoclonal antibody is designed to address the IgA-driven process underlying Immunoglobulin A Nephropathy. The Phase 2 study evaluates its effect on change in proteinuria in adults with IgAN.
ARGX-121 is being developed by argenx SE, which trades under the ticker ARGX. The company is running the Phase 2 program in Immunoglobulin A Nephropathy across sites in the United States and Japan.
ARGX-121 is in Phase 2 clinical development for Immunoglobulin A Nephropathy. It is investigational and has not completed its clinical program. The single registered Phase 2 trial is not yet recruiting and is planned to enroll 120 adult participants.
ARGX-121 is being studied in one Phase 2 trial, NCT07773727, titled a study to evaluate the effect of ARGX-121 on the change in proteinuria in adult participants with IgAN. The trial is randomized, double-blind, and placebo-controlled, plans to enroll 120 participants, and is not yet recruiting in the United States and Japan.